Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DAG181 · 2 trials · 1 indication
SVR12 is defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 12 weeks after discontinuation of therapy
Collecting all adverse events during the whole study
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment
| Arm | Type | Description |
|---|---|---|
| SOF 400 mg+DAG181 100 mg | EXPERIMENTAL | Patients with genotype 1 HCV infection without cirrhosis will receive SOF 400 mg+DAG181 100 mg for 12 weeks. |
| SOF+DAG181 100 mg | EXPERIMENTAL | Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 100 mg for 12 weeks. |
| SOF+DAG181 200 mg | EXPERIMENTAL | Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 200 mg for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| SOF | DRUG | 400 mg tablet administered orally once daily |
| DAG181 | DRUG | 100 mg capsule administered orally once daily |
Inclusion Criteria: 1. Willing and able to provide written informed consent; 2. Male or female, age≥18 years; 3. A female subject is eligible to enter the study if it is confirmed that she is: 1. Of non-childbearing potential (i.e., women who have had a hysterectomy, have both ovaries removed o...